相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。HDAC1 activates FoxO and is both sufficient and required for skeletal muscle atrophy
Adam W. Beharry et al.
JOURNAL OF CELL SCIENCE (2014)
Cellular and molecular mechanisms of muscle atrophy
Paolo Bonaldo et al.
DISEASE MODELS & MECHANISMS (2013)
Biochemistry and pathophysiology of intravascular and intracellular lipolysis
Stephen G. Young et al.
GENES & DEVELOPMENT (2013)
Acetylation and deacetylation-novel factors in muscle wasting
Nima Alamdari et al.
METABOLISM-CLINICAL AND EXPERIMENTAL (2013)
The role of triglyceride lipases in cancer associated cachexia
Suman K. Das et al.
TRENDS IN MOLECULAR MEDICINE (2013)
Metabolic derangements in the gastrocnemius and the effect of Compound A therapy in a murine model of cancer cachexia
Hirak Der-Torossian et al.
JOURNAL OF CACHEXIA SARCOPENIA AND MUSCLE (2013)
Atrogin-1, MuRF-1, and sarcopenia
Jonathan P. Gumucio et al.
ENDOCRINE (2013)
Disruption of MEF2C signaling and loss of sarcomeric and mitochondrial integrity in cancer-induced skeletal muscle wasting
Angie M. Y. Shum et al.
AGING-US (2012)
Cancer Cachexia: Mediators, Signaling, and Metabolic Pathways
Kenneth C. H. Fearon et al.
CELL METABOLISM (2012)
Current pharmacotherapy options for cancer anorexia and cachexia
Antonio Maccio et al.
EXPERT OPINION ON PHARMACOTHERAPY (2012)
Inhibition of FoxO transcriptional activity prevents muscle fiber atrophy during cachexia and induces hypertrophy
Sarah A. Reed et al.
FASEB JOURNAL (2012)
The role of insulin resistance in the development of muscle wasting during cancer cachexia
Mary A. Honors et al.
JOURNAL OF CACHEXIA SARCOPENIA AND MUSCLE (2012)
p300 Acetyltransferase activity differentially regulates the localization and activity of the FOXO homologues in skeletal muscle
Sarah M. Senf et al.
AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY (2011)
Biomarker identification in non-small cell lung cancer (NSCLC) with activity-based proteomics
Thomas Wiedl et al.
CANCER RESEARCH (2011)
Chemoproteomics profiling of HDAC inhibitors reveals selective targeting of HDAC complexes
Marcus Bantscheff et al.
NATURE BIOTECHNOLOGY (2011)
Learning to predict cancer-associated skeletal muscle wasting from 1H-NMR profiles of urinary metabolites
Roman Eisner et al.
METABOLOMICS (2011)
Treating cancer cachexia to treat cancer
Se-Jin Lee et al.
SKELETAL MUSCLE (2011)
Evidence for the contribution of insulin resistance to the development of cachexia in tumor-bearing mice
Michelle L. Asp et al.
INTERNATIONAL JOURNAL OF CANCER (2010)
The Novel Deacetylase Inhibitor AR-42 Demonstrates Pre-Clinical Activity in B-Cell Malignancies In Vitro and In Vivo
David M. Lucas et al.
PLOS ONE (2010)
α-Hydroxybutyrate Is an Early Biomarker of Insulin Resistance and Glucose Intolerance in a Nondiabetic Population
Walter E. Gall et al.
PLOS ONE (2010)
Cachexia as a major underestimated and unmet medical need: facts and numbers
Stephan von Haehling et al.
JOURNAL OF CACHEXIA SARCOPENIA AND MUSCLE (2010)
Deacetylase Inhibitors Modulate the Myostatin/Follistatin Axis without Improving Cachexia in Tumor-Bearing Mice
A. Bonetto et al.
CURRENT CANCER DRUG TARGETS (2009)
Histone Deacetylase Inhibitors in Cancer Therapy
Andrew A. Lane et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
A Rationally Designed Histone Deacetylase Inhibitor with Distinct Antitumor Activity against Ovarian Cancer
Ya-Ting Yang et al.
NEOPLASIA (2009)
OSU-HDAC42, a Histone deacetylase inhibitor, blocks prostate tumor progression in the transgenic adenocarcinoma of the mouse prostate model
Aaron M. Sargeant et al.
CANCER RESEARCH (2008)
Efficacy of a novel histone deacetylase inhibitor in murine models of hepatocellular carcinoma
Yen-Shen Lu et al.
HEPATOLOGY (2007)
Oxidative stress, chronic disease, and muscle wasting
Jennifer S. Moylan et al.
MUSCLE & NERVE (2007)
Antitumor effects of a novel phenylbutyrate-based histone deacetylase inhibitor, (S)-HDAC-42, in prostate cancer
Samuel K. Kulp et al.
CLINICAL CANCER RESEARCH (2006)
Differential metabolomics reveals ophthalmic acid as an oxidative stress biomarker indicating hepatic glutathione consumption
Tomoyoshi Soga et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2006)
The AP-1/CJUN signaling cascade is involved in muscle differentiation:: Implications in muscle wasting during cancer cachexia
R Moore-Carrasco et al.
FEBS LETTERS (2006)
Foxo transcription factors induce the atrophy-related ubiquitin ligase atrogin-1 and cause skeletal muscle atrophy
M Sandri et al.
CELL (2004)
Skeletal muscle FOXO1 (FKHR) transgenic mice have less skeletal muscle mass, down-regulated type I (slow twitch/red muscle) fiber genes, and impaired glycemic control
Y Kamei et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
Cancer cachexia is regulated by selective targeting of skeletal muscle gene products
S Acharyya et al.
JOURNAL OF CLINICAL INVESTIGATION (2004)
Multiple types of skeletal muscle atrophy involve a common program of changes in gene expression
SH Lecker et al.
FASEB JOURNAL (2004)
Effects of FK228, a novel histone deacetylase inhibitor, on human lymphoma U-937 cells in vitro and in vivo
Y Sasakawa et al.
BIOCHEMICAL PHARMACOLOGY (2002)
Muscle UCP-3 mRNA levels are elevated in weight loss associated with gastrointestinal adenocarcinoma in humans
P Collins et al.
BRITISH JOURNAL OF CANCER (2002)
Identification of ubiquitin ligases required for skeletal muscle atrophy
SC Bodine et al.
SCIENCE (2001)
分享论文
